Avadel Pharmaceuticals PLC (STU:AWK)
€ 10 0.15 (1.52%) Market Cap: 949.15 Mil Enterprise Value: 888.38 Mil PE Ratio: 0 PB Ratio: 13.69 GF Score: 42/100

Avadel Pharmaceuticals PLC REST-ON Phase 3 Trial Data Call Transcript

Apr 27, 2020 / 12:30PM GMT
Release Date Price: €8.85 (+3.51%)
Operator

Greetings, and welcome to the Avadel Pharmaceuticals data call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Tom McHugh, Chief Financial Officer. Please go ahead, sir.

Thomas S. McHugh
Avadel Pharmaceuticals plc - Senior VP & CFO

Good morning, and thank you for joining us on our conference call. On the call with me today are Greg Divis, Chief Executive Officer; and Dr. Jordan Dubow, Chief Medical Officer of Avadel. This morning, we should have released with top line data results from the Phase III REST-ON study. The release can be accessed on our website, www.avadel.com.

As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot